Description: Discover the potent precision of Alymsys® Monoclonal Antibody, a cutting-edge targeted therapy offering innovative treatment possibilities
Alymsys® (bevacizumab-maly) injection is similar to Avastin® (bevacizumab) based on the totality of evidence, with no clinically meaningful differences in efficacy, safety and immunogenicity 1-6 . Bevacizumab is an antineoplastic agent, inhibiting angiogenesis by specifically binding to the vascular endothelial growth factor (VEGF) 1,2 .
Over 60,000 patients have been treated with Alymsys worldwide.
Multiple in vitro analytical similarity studies using state-of-the-art orthogonal analytical methods demonstrated similarity between Alymsys® and Avastin® in key features such as: primary structure, molecular conformation, glycosylation, charge variants, protein content, purity and biological activity. 1